Baxalta — Q3 2015 Earnings Presentation
34 slides from Baxalta's earnings presentation, Oct 29, 2015
Slide 1: Third Quarter 2015 Financial Results & Business Performance Update
Baxalta Incorporated Third Quarter 2015 Financial Results & Business Performance Update October 29 th , 2015 Exhibit 99.2
Slide 2: Earnings Conference Call Agenda
Baxalta Performance Update | Q3 2015 | Page 2 Third Quarter 2015 Earnings Conference Call Agenda Introduction Mary Kay Ladone Opening Remarks Ludwig Hantson, Ph.D. Innovation Update John Orloff, M.D. Financial Performance & Outlook Robert Hombach Questions & Answers Management Team Robert Hombach Ex
Slide 3: Delivering Shareholder Value By Executing Our Strategy
Ludwig Hantson, Ph.D. Delivering Shareholder Value By Executing Our Strategy
Slide 4: Strong Execution Validates Baxalta's Commitment To Driving Shareholder Value
Baxalta Performance Update | Q3 2015 | Page 5 Achieving ~20 new product launches by 2020 • Advancing the pipeline with key milestone achievements • Driving enhanced value from new products with 2015 sales of ~$280 million • Delivering risk-adjusted revenues of $2.8B by 2020 and $7.0B by 2025 Generat
Slide 5: Driving Strong Q3 2015 Financial Results
Baxalta Performance Update | Q3 2015 | Page 6 *Growth rates are at constant currency and compare to 2014 pro forma sales **Financial results and guidance exclude special items and are presented on an adjusted basis; refer to slides 31-36 for information regarding non-GAAP measures used throughout th
Slide 6: Building Three Sustainable Businesses
Baxalta Performance Update | Q3 2015 | Page 7 Treating unmet medical needs and orphan diseases Innovating in a focused, targeted manner Leveraging patient centricity and high touch models Ensuring sustainable, high quality supply Enhancing access and standards of care Capitalizing on differentiated
Slide 7: Advancing Portfolio With Significant Regulatory Success
Baxalta Performance Update | Q3 2015 | Page 8 7 Regulatory Approvals 4 Products Under Review Advancing Portfolio With Significant Regulatory Success ADYNOVATE (U.S.) VONVENDI (U.S.) 20% IGSC (U.S./EU) nal-IRI (EU)
Slide 8: New Product Sales Contribution
Baxalta Performance Update | Q3 2015 | Page 9 ~30% 50%+ 10%+ New Product Sales (Risk-Adjusted) Meaningful Revenue Contribution Beyond 2020 $0 $2 $4 $6 $8 2015 Expectation 2016 Expectation 2020 Outlook 2025 Outlook Risk Adjusted 0% 20% 40% 60% 80% 100% 2015 Expectation 2016 Expectation 2020 Outlook 2
Slide 9: Substantial Revenues From Late-Stage Assets
Baxalta Performance Update | Q3 2015 | Page 10 Hematology Hematology Immunology Immunology Oncology Oncology 2020 New Product Sales 2020 New Product Sales Substantial Revenues From Late-Stage Assets ~90% of Revenues from products that are approved, under regulatory review, or have positive phase III
Slide 10: Multiple R&D Programs With Revenue Potential Of $500+ Million
Baxalta Performance Update | Q3 2015 | Page 11 HYQVIA 20% IGSC ADYNOVATE VONVENDI Pacritinib nal-IRI ONCASPAR BAX 826 Gene Therapy SuppreMol Biosimilars IMALUMAB Multiple R&D Programs With Revenue Potential Of $500+ Million Oncology Immunology Hematology Early-Stage Assets Recent Product Launches/ L
Slide 11: Advancing External Innovation
Baxalta Performance Update | Q3 2015 | Page 12 Acquisitions Partnerships Advancing External Innovation
Slide 12: Enhancing Growth With M&A Initiatives
Baxalta Performance Update | Q3 2015 | Page 13 Enhancing Growth With M&A Initiatives M&A Strategic Principles • Focusing on value-creation • Evaluating opportunities with strong strategic fit across core therapeutic orphan disease areas: Hematology Immunology Oncology • Enhancing integration success
Slide 13: Baxalta: A Compelling & Unique Investment Opportunity
Baxalta Performance Update | Q3 2015 | Page 14 Leadership Capabilities Value Baxalta: A Compelling & Unique Investment Opportunity • Established $6 billion global biopharmaceutical leader focused on orphan diseases • Well positioned in attractive and growing markets with differentiated therapies • S
Slide 14: Innovation Update
John Orloff, M.D. Innovation Update
Slide 15: Achieving Key Milestones
Baxalta Performance Update | Q3 2015 | Page 16 ADYNOVATE VONVENDI OBIZUR Gene Therapy FIX 20% IGSC BAX 923 Sanquin ONCASPAR nal-IRI Pacritinib Achieving Key Milestones U.S. regulatory approval pending; favorable FDA late-cycle review U.S. regulatory approval pending; favorable FDA late-cycle review
Slide 16: g s &
g s &
Slide 17: Financial Performance
Bob Hombach Financial Performance
Slide 18: Q3 2015 Revenues
Baxalta Performance Update | Q3 2015 | Page 19 5% 6% 8% 13% 8% 7% 13% *2015 growth rates compare to 2014 pro forma sales; 2014 constant currency growth rates do not include pro forma adjustments U.S. International Q3 2015 Revenues Worldwide Revenues* $ In Billions 0% 5% 10% 15% Q1 14 Q2 14 Q3 14 Q4
Slide 19: Hematology
Baxalta Performance Update | Q3 2015 | Page 20 Hematology Hemophilia • Enhancing access and elevating standards of care globally • Global ADVATE growth in double-digits: - Continued rFVIII conversion in Brazil - U.S. sales growth in mid single digits - Cumulative U.S. patient share loss of 2-3 point
Slide 20: Hematology Sales Growth
Baxalta Performance Update | Q3 2015 | Page 21 9% 7% 9% 8% 2% 4% 7% 9% 2% 17% 33% 18% 12% 22% 0% 5% 10% 15% 20% Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Hematology Sales Growth Hemophilia % Sales Growth At Constant Currency 0% 10% 20% 30% 40% Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Inhibitor Ther
Slide 21: Immunology
Baxalta Performance Update | Q3 2015 | Page 22 *Growth rates compare to 2014 pro forma sales Immunology* Immunoglobulin Therapies • Enhancing penetration in under- treated diseases • Capitalizing on broad and differentiated portfolio - Higher demand in Primary Immunodeficiency segment - Improved sup
Slide 22: Immunology Sales Growth
Baxalta Performance Update | Q3 2015 | Page 23 2% 3% -2% 13% 9% 13% 12% -11% 15% 21% 19% 24% 4% 14% *2014 constant currency growth rates do not include pro forma adjustments -5% 0% 5% 10% 15% Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Immunology Sales Growth Immunoglobulin Therapies % Sales Growth At
Slide 23: Oncology
Baxalta Performance Update | Q3 2015 | Page 24 Leveraging expertise in orphan diseases, high touch, service intensive therapies Focusing on targeted populations with limited treatment options Capitalizing on attractive and growing market Partnering with leading R&D companies on transformational scie
Slide 24: Q3 2015 Financial Results
Baxalta Performance Update | Q3 2015 | Page 25 Q3 2015 *Financial results exclude special items and are presented on an adjusted basis; refer to slides 31-36 for information regarding non-GAAP measures used throughout the presentation Q3 2015 Financial Results* Sales ($ in Millions) $1,595 Gross Mar
Slide 25: Financial Outlook
Bob Hombach Financial Outlook
Slide 26: 2015 Full Year Sales Growth Expectations
Baxalta Performance Update | Q3 2015 | Page 27 FY 2015 Original* (Q1 Conference Call) FY 2015 Guidance** (Q2 Conference Call) FY 2015 Guidance** (Revised) Baxalta ~4% 6% - 7% ~8% *FY 2015 original guidance does not include pro forma adjustments **Growth compares to 2014 pro forma sales; H1 2015 resu
Slide 27: 2H 2015 Financial Outlook
Baxalta Performance Update | Q3 2015 | Page 28 Q3 2015 Actual Results Q4 2015 Guidance 2H 2015 Guidance (Revised) *Financial results and guidance presented on an adjusted basis; refer to slides 31-36 for additional information **Growth rates are at constant currency and compare to 2014 pro forma sal
Slide 28: Raising 2H 2015 Financial Guidance
Baxalta Performance Update | Q3 2015 | Page 29 2H 2015 Guidance (Investor Conference) 2H 2015 Guidance (Q2 Conference Call) 2H 2015 Guidance (Revised) *Financial guidance presented on an adjusted basis; refer to slides 31-36 for additional information **Growth rates are at constant currency and comp
Slide 29: Preliminary Full Year 2016 Financial Guidance
Baxalta Performance Update | Q3 2015 | Page 30 FY 2016 Guidance (Investor Conference) FY 2016 Guidance (Revised) *Financial guidance presented on an adjusted basis; refer to slides 31-36 for additional information **Growth rates are at constant currency and compare to 2015 pro forma sales Preliminar
Slide 30: GAAP to Pro Forma Non-GAAP Reconciliations
GAAP to Pro Forma Non-GAAP Reconciliations
Slide 31: Pro Forma Sales Reconciliation
Baxalta Performance Update | Q3 2015 | Page 33 Hematology $415 $520 $935 $373 $569 $942 11% (9%) (1%) 11% 9% 10% Pro Forma Immunology $398 $228 $626 $365 $223 $588 9% 2% 6% 9% 18% 13% Oncology $28 $6 $34 $ - $ - $ - N/M N/M N/M N/M N/M N/M Hematology $1,174 $1,423 $2,597 $1,089 $1,584 $2,673 8% (10%
Slide 32: GAAP-to-Non-GAAP Reconciliation: Gross Margin
Baxalta Performance Update | Q3 2015 | Page 34 GAAP-to-Non-GAAP Reconciliation: Gross Margin $ in millions Q3 2015 Gross Margin Gross Margin Percentage 60.3% Adjustments for special items Adjusted Gross Margin Adjusted Gross Margin Percentage 61.9% Baxalta has also presented guidance for H2 2015 and
Slide 33: GAAP-to-Non-GAAP Reconciliation: Operating Income and EBITDA
Baxalta Performance Update | Q3 2015 | Page 35 GAAP-to-Non-GAAP Reconciliation: Operating Income and EBITDA $ in millions Q3 2015 Pre-tax Income Pre-tax Income Margin 22.2% Adjustments for special items Adjusted Pre-tax Income Adjusted Pre-tax Income Margin 31.0% Remove: Net interest expense Remove:
Slide 34: GAAP-to-Non-GAAP Reconciliation: Diluted EPS
Baxalta Performance Update | Q3 2015 | Page 36 GAAP-to-Non-GAAP Reconciliation: Diluted EPS Q3 2015 Diluted EPS $0.45 Adjustments for special items 0.11 Adjusted Diluted EPS $0.56 Baxalta has also presented guidance for Q4 2015, H2 2015 and 2016 using the non- GAAP measure of Adjusted Diluted EPS. B